Corboy JR, Fox RJ, Kister I, Cutter GR, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 2023;22:568-577.
PMID: 37353277